Latest Product Development News

Lumos Diagnostics has voluntarily suspended its ASX trading pending a market announcement about strategic agreements, signaling potential shifts in its business trajectory.

Locate Technologies has successfully raised $168,915 through its At-the-Market Facility, reinforcing its financial position as it continues to develop its delivery optimisation platforms.

ClearVue Technologies initiates a thorough expenditure review and announces a key board resignation as it aims to sharpen its focus on product innovation and global expansion.

ikeGPS has successfully raised A$18 million through a fully underwritten placement, supported by strong investor demand, and is launching a A$2 million share purchase plan to fund new product development and strategic initiatives.

Bio-Gene Technology Limited has announced an offer of over 95 million Placement Options to investors and its Lead Manager, contingent on shareholder approval at an upcoming extraordinary general meeting. If exercised, these options could inject approximately $3.8 million into the company.

Spacetalk Ltd has raised $3 million through convertible notes from its largest shareholder and converted $1 million of secured debt, positioning the company for international growth and new product development.

Hydralyte USA has completed its Rights Issue by placing 5 million shortfall shares, raising a total of $608,878 before costs. The move finalizes the company’s recent capital raising efforts under full regulatory compliance.

ikeGPS Group Limited has announced a fully underwritten A$18 million placement and a A$2 million share purchase plan to fund new product development and expand its market leadership in North America's utility software sector.

archTIS Limited has successfully raised $7.5 million through a share placement, aiming to fuel its international growth strategy focused on U.S. market expansion, strategic partnerships, and product development.

Acrux Limited has secured a further $0.46 million advance on its FY25 R&D Tax Incentive, bringing total advances to $2.19 million and supporting its pharmaceutical product development and working capital needs.

archTIS Limited has secured A$7.5 million through a discounted share placement to fund expansion in the U.S. defence sector, deepen strategic partnerships, and accelerate product innovation focused on secure data collaboration.

Orthocell Limited has posted a record quarterly revenue of A$2.73 million, driven by strong Australian sales of its nerve repair product Remplir™, with US market expansion poised to accelerate in FY26.